Pomerantz Roger

SEC source: 0001641172-25-014695 · ownership.xml · derivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-06-10

F1 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2026.

SEC source: 0001641172-25-003825 · ownership.xml · derivative · entry 3

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 250 shares

Expires 2025-06-28

F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation.

SEC source: 0001641172-25-003825 · ownership.xml · derivative · entry 2

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 250 shares

Expires 2026-06-28

F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation.

SEC source: 0001641172-25-003825 · ownership.xml · derivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 500 shares

Expires 2027-07-15

F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation.

SEC source: 0000950170-24-131475 · ownership.xml · derivative · entry 2

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,069

Underlying: Common Stock · 9,034 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F2 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.

F2 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.

SEC source: 0000950170-24-131475 · ownership.xml · nonDerivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,478

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0000950170-24-106026 · ownership.xml · derivative · entry 2

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,103

Underlying: Common Stock · 9,034 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F2 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F2 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0000950170-24-106026 · ownership.xml · nonDerivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,444

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0000950170-24-076990 · ownership.xml · derivative · entry 2

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,750

Underlying: Common Stock · 18,750 shares

Expires 2034-06-20

F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date.

SEC source: 0000950170-24-076990 · ownership.xml · derivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-06-20

F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date.

SEC source: 0001493152-24-023149 · ownership.xml · derivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2034-06-06

F1 · derivative.exercise_date: The stock option vests and becomes exercisable on June 6, 2025.

SEC source: 0000950170-24-066146 · ownership.xml · derivative · entry 2

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,137

Underlying: Common Stock · 9,035 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F2 · deemedExecutionDate: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.

F2 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.

F2 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.

SEC source: 0000950170-24-066146 · ownership.xml · nonDerivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,410

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-24-004039 · doc4.xml · derivative · entry 2

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,172

Underlying: Common Stock · 9,034 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F2 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.

F2 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.

SEC source: 0001209191-24-004039 · doc4.xml · nonDerivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,375

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-23-056838 · doc4.xml · derivative · entry 2

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,206

Underlying: Common Stock · 9,034 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F2 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.

F2 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.

SEC source: 0001209191-23-056838 · doc4.xml · nonDerivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,341

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-23-047668 · doc4.xml · derivative · entry 2

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,240

Underlying: Common Stock · 9,034 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F2 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.

F2 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.

SEC source: 0001209191-23-047668 · doc4.xml · nonDerivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,307

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-23-046585 · doc4.xml · derivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2033-08-16

F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month following the Vesting Commencement Date (as defined below), or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date. The Vesting Commencement Date is June 9, 2023.

SEC source: 0001209191-23-036021 · doc4.xml · derivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-06-08

F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date.

SEC source: 0001209191-23-032709 · doc4.xml · derivative · entry 2

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,274

Underlying: Common Stock · 9,035 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F2 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F2 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-23-032709 · doc4.xml · nonDerivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,273

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001493152-23-019460 · ownership.xml · derivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-05-25

F1 · derivative.exercise_date: The stock option vests and becomes exercisable on May 25, 2024.

SEC source: 0001209191-23-013857 · doc4.xml · derivative · entry 2

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,309

Underlying: Common Stock · 9,034 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F2 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F2 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-23-013857 · doc4.xml · nonDerivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,238

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-22-058972 · doc4.xml · derivative · entry 2

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,343

Underlying: Common Stock · 9,034 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F2 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F2 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-22-058972 · doc4.xml · nonDerivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,204

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001493152-22-027438 · ownership.xml · derivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,000

Underlying: Common Stock · 81,000 shares

Expires 2032-09-30

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-half of the total shares on September 30, 2023 and thereafter the remaining shares vest and become exercisable on September 30, 2024.

SEC source: 0001209191-22-047949 · doc4.xml · derivative · entry 2

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,377

Underlying: Common Stock · 9,034 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F2 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F2 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-22-047949 · doc4.xml · nonDerivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,170

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-22-045494 · doc4.xml · derivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,282

Underlying: Common Stock · 30,282 shares

Expires 2032-08-10

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the Option shall vest each month following the Vesting Commencement Date (as defined below), on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), or if earlier one hundred percent (100%) of the shares subject to the Option shall vest on the date of the Company's next annual stockholder meeting, in each case subject to the Participant continuing to be a Service Provider (as defined in the Company's 2021 Equity Incentive Plan) through each such date. The Vesting Commencement Date is July 29, 2022.

SEC source: 0001209191-22-036012 · doc4.xml · derivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-06-09

F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date.

SEC source: 0001209191-22-032666 · doc4.xml · derivative · entry 2

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,411

Underlying: Common Stock · 9,034 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F2 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F2 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-22-032666 · doc4.xml · nonDerivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,136

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-22-014440 · doc4.xml · derivative · entry 2

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,445

Underlying: Common Stock · 9,034 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F2 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F2 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-22-014440 · doc4.xml · nonDerivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,102

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-22-010972 · doc4.xml · derivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2032-02-15

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal quarterly installments with 6.25% of the total underlying shares vesting at the end of each quarter following the vesting commencement date, subject to continued service with the issuer through each vesting date.

SEC source: 0001209191-21-067047 · doc4.xml · derivative · entry 2

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,479

Underlying: Common Stock · 18,068 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F2 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F2 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-21-067047 · doc4.xml · nonDerivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,068

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001493152-21-018909 · ownership.xml · derivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,000

Underlying: Common Stock · 41,000 shares

Expires 2031-08-04

F1 · derivative.exercise_date: The stock option vests and becomes exercisable on August 4, 2022.

SEC source: 0001209191-21-026551 · doc4.xml · derivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 254,000

Underlying: Common Stock · 254,000 shares

Expires 2031-04-08

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal quarterly installments with 6.25% of the total underlying shares vesting at the end of each quarter following the vesting commencement date, subject to continued service with the issuer through each vesting date.

SEC source: 0001209191-21-023651 · doc4.xml · derivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Common Stock · 135,000 shares

Expires 2031-03-26

F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the Shares subject to the Option shall vest on the one (1) month anniversary of March 1, 2021 (the "Vesting Commencement Date"), and one thirty-sixth (1/36th) of the Shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Therapeutics, Inc. 2021 Equity Incentive Plan) through each such date.

SEC source: 0001213900-20-017813 · ownership.xml · derivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Ordinary Shares · 40,000 shares

Expires 2027-07-15

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the total shares on July 15, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 15, 2023.

SEC source: 0001213900-19-011972 · ownership.xml · derivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Ordinary Shares · 20,000 shares

Expires 2026-06-28

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the total shares on June 28, 2020 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through June 28, 2022.

SEC source: 0000899243-19-017036 · doc4.xml · derivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2029-06-12

F1 · derivative.exercise_date: The option will vest in full on the earlier of June 13, 2020 or the day immediately prior to the company's 2020 annual meeting of shareholders.

SEC source: 0000899243-18-024194 · doc4.xml · nonDerivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 213,976

F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018.

F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.03. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-18-023938 · doc4.xml · nonDerivative · entry 2

Pomerantz Roger · CIK 0001614936 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,786

F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018.

F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.17. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-18-023938 · doc4.xml · nonDerivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 218,799

F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018.

F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.26. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-18-046530 · a4.xml · nonDerivative · entry 1

Pomerantz Roger · CIK 0001614936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100